<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
<channel>


<title>aktiencheck.de - Forum - DSM-Firmenich AG</title>
<link>http://www.aktiencheck.de</link>
<description>aktiencheck.de</description>
<language></language>
<copyright>aktiencheck.de</copyright>
<lastBuildDate>Tue, 26 May 2026 19:17:19 +0200</lastBuildDate>
<ttl>2</ttl>








<item>
<title>DSM-Firmenich (WKN: A3D2TK)</title>
<link>http://www.aktiencheck.de/forum/DSM_Firmenich_WKN_A3D2TK-A3D2TK-t582938</link>
<guid>http://www.aktiencheck.de/forum/DSM_Firmenich_WKN_A3D2TK-A3D2TK-t582938</guid>
<description>Q, Kaiseraugst (Switzerland), Maastricht (Netherlands), July 30, 2024

Management Report
H1 2024 Highlights
Strong improvement of financial results
Synergies and vitamin transformation program on track, with €95 million delivered in the first six months
Mid-term strategy defined, including financial targets and sustainability ambitions
Portfolio fine-tuning progressing with divestments of yeast extracts and marine lipids already announced
Animal Nutrition &amp; Health separation well advanced
FY 2024 outlook increased: Adjusted EBITDA around €2 billion



https://www.dsm-firmenich.com/corporate/news/press-releases/2024/dsm-firmenich-reports-h1-2024-results. [&lt;a href=&#034;http://www.aktiencheck.de/forum/DSM_Firmenich_WKN_A3D2TK-A3D2TK-t582938&#034;&gt;mehr&lt;/a&gt;]</description>
</item>

</channel>
</rss>







